Protagonist GAAP EPS of -$0.69 misses by $0.20, revenue of $7.44M
Source: SeekingAlpha
2026-02-25 17:45:42 ET
More on Protagonist
- Protagonist Therapeutics: Assessing The 2026 Upside For Icotrokinra And Rusfertide
- Protagonist Therapeutics, Inc. (PTGX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- ClearBridge Small-Cap Growth trims Duolingo, Biohaven, QLYS; Adds PTGX, SSD, BETA, DYN in Q4
- Seeking Alpha’s Quant Rating on Protagonist
- Historical earnings data for Protagonist
Read the full article on Seeking Alpha
For further details see:
Protagonist GAAP EPS of -$0.69 misses by $0.20, revenue of $7.44M
Protagonist Therapeutics Inc.
NASDAQ: PTGX
PTGX Trading
4.08% G/L:
$95.07 Last:
198,331 Volume:
$91.14 Open:
PTGX Latest News
March 02, 2026 02:00:00 am
Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera
February 25, 2026 05:15:00 pm
CORRECTION: Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
February 25, 2026 04:05:00 pm
Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
February 25, 2026 03:48:39 pm
Protagonist Stock Up 120%, but One Fund Just Revealed a $170 Million Exit
PTGX Stock Data
$5,268,820,330
53,263,347
0.64%
112
N/A
Biotechnology & Life Sciences
Healthcare
US
Newark
